World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   316 records for 41 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4 5
Recruitment statusProspective RegistrationMain ID Public TitleDate of RegistrationResults available
RecruitingNoCTRI/2017/09/009894
Heat therapy(agnikarma) in Tennis Elbow
22-09-2017 
RecruitingYesISRCTN14389453
Study of self-perceived psychological and emotional well-being of young Paralympic athletes
29/06/2017 
RecruitingYesNCT02709408
European Prospective Cohort Study on Enterobacteriaceae Showing Resistance to Carbapenems
02/03/2016 
AuthorisedYesEUCTR2015-000515-41-CZ
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AFTER FAILURE OF ONE PRIOR PLATINUM-CONTAINING CHEMOTHERAPY REGIMEN
Recruitment statusMain IDPublic titleDate of registrationResults available
AuthorisedEUCTR2015-000515-41-ES A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AFTER FAILURE OF ONE PRIOR PLATINUM-CONTAINING CHEMOTHERAPY REGIMEN 31/07/2015 
AuthorisedEUCTR2015-000515-41-IT A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AFTER FAILURE OF ONE PRIOR PLATINUM CONTAINING CHEMOTHERAPY REGIMEN. 30/09/2016 
AuthorisedEUCTR2015-000515-41-SK A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AFTER FAILURE OF ONE PRIOR PLATINUM-CONTAINING CHEMOTHERAPY REGIMEN 27/10/2015 
AuthorisedEUCTR2015-000515-41-HU A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AFTER FAILURE OF ONE PRIOR PLATINUM-CONTAINING CHEMOTHERAPY REGIMEN 16/07/2015 
AuthorisedEUCTR2015-000515-41-PL A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AFTER FAILURE OF ONE PRIOR PLATINUM-CONTAINING CHEMOTHERAPY REGIMEN 09/09/2015 
RecruitingNCT02499120 Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer 13/07/2015 
30/06/2015 
Not RecruitingYesCTRI/2015/03/005597
To compare the effect of Tiotropium 5 ug and Olodaterol 5 ug in fixed dose combination over Tiotropium 5 ug in reducing Moderate to severe worsening of a disease in patients with severe to very severe Chronic Obstructive Pulmonary disease
02-03-2015 
AuthorisedYesEUCTR2014-002275-28-IT
Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.
Recruitment statusMain IDPublic titleDate of registrationResults available
AuthorisedEUCTR2014-002275-28-HU Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease. 19/11/2014 
AuthorisedEUCTR2014-002275-28-BE Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease. 18/11/2014 
AuthorisedEUCTR2014-002275-28-GB Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease. 24/11/2014 
Not RecruitingEUCTR2014-002275-28-LV Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease. 05/01/2015 
Not RecruitingEUCTR2014-002275-28-CZ Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease. 29/12/2014 
Not RecruitingEUCTR2014-002275-28-FI Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease. 28/10/2014 
Not RecruitingEUCTR2014-002275-28-BG Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease. 05/03/2015 
Not RecruitingEUCTR2014-002275-28-NL Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease. 18/11/2014 
Not RecruitingEUCTR2014-002275-28-ES Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease. 25/11/2014 
Not RecruitingEUCTR2014-002275-28-AT Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease. 27/11/2014 
Not RecruitingEUCTR2014-002275-28-SE Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease. 10/11/2014 
Not RecruitingEUCTR2014-002275-28-IE Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease. 28/11/2014 
Not RecruitingEUCTR2014-002275-28-LT Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease. 29/12/2014 
Not RecruitingEUCTR2014-002275-28-DK Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease. 13/11/2014 
Not RecruitingEUCTR2014-002275-28-PT Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease. 10/11/2014 
Not RecruitingEUCTR2014-002275-28-DE Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease. 13/01/2015 
Not RecruitingEUCTR2014-002275-28-PL Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease. 09/04/2015 
Not recruitingNCT02296138 Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease. 19/11/2014 
Not RecruitingEUCTR2014-002275-28-SK Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease. 07/01/2015 
Not RecruitingEUCTR2014-002275-28-GR Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease. 29/01/2015 
Not RecruitingEUCTR2014-002275-28-SI Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease. 22/01/2015 
Not RecruitingEUCTR2014-002275-28-HR Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease. 02/04/2015 
28/10/2014 
Not RecruitingYesEUCTR2013-000490-79-GR
Study to evaluate 2 types of treatment (masitinib + FOLFIRI or placebo + FOLFIRI) in the treatment of patients with metastatic colorectal cancer that have received 1 previous therapy
Recruitment statusMain IDPublic titleDate of registrationResults available
AuthorisedEUCTR2013-000490-79-FR Study to evaluate 2 types of treatment (masitinib + FOLFIRI or placebo + FOLFIRI) in the treatment of patients with metastatic colorectal cancer that have received 1 previous therapy 16/06/2015 
AuthorisedEUCTR2013-000490-79-HU Study to evaluate 2 types of treatment (masitinib + FOLFIRI or placebo + FOLFIRI) in the treatment of patients with metastatic colorectal cancer that have received 1 previous therapy 06/06/2014 
Not RecruitingEUCTR2013-000490-79-ES Study to evaluate 2 types of treatment (masitinib + FOLFIRI or placebo + FOLFIRI) in the treatment of patients with metastatic colorectal cancer that have received 1 previous therapy 22/05/2014 
Not RecruitingEUCTR2013-000490-79-GB A specially designed study conducted at many medical sites to compare whether Masitinib, in combination with a currently available medicine called Folfiri, to placebo in combination with Folfiri, is safe and effective in second line treatment of patients with advanced colorectal cancer. 07/07/2014 
Not RecruitingEUCTR2013-000490-79-CZ Study to evaluate 2 types of treatment (masitinib + FOLFIRI or placebo + FOLFIRI) in the treatment of patients with metastatic colorectal cancer that have received 1 previous therapy 28/05/2014 
Not RecruitingEUCTR2013-000490-79-SK Study to evaluate 2 types of treatment (masitinib + FOLFIRI or placebo + FOLFIRI) in the treatment of patients with metastatic colorectal cancer that have received 1 previous therapy 29/05/2014 
30/01/2014 
AuthorisedYesEUCTR2012-005012-26-BE
A CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES
Recruitment statusMain IDPublic titleDate of registrationResults available
AuthorisedEUCTR2012-005012-26-ES A CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES 12/11/2013 
AuthorisedEUCTR2012-005012-26-IT A CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES 04/10/2013 
AuthorisedEUCTR2012-005012-26-HU A CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES 11/11/2013 
Not AvailableEUCTR2012-005012-26-Outside-EU/EEA A CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES 18/06/2014 
AuthorisedEUCTR2012-005012-26-LV A CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES 14/04/2014 
AuthorisedEUCTR2012-005012-26-RO A CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES 13/05/2014 
AuthorisedEUCTR2012-005012-26-EE A CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES 16/01/2014 
AuthorisedEUCTR2012-005012-26-GR A CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES 02/10/2015 
AuthorisedEUCTR2012-005012-26-SK A CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES 07/11/2013 
AuthorisedEUCTR2012-005012-26-SI A CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES 08/10/2014 
AuthorisedEUCTR2012-005012-26-FR A CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES 28/09/2015 
AuthorisedEUCTR2012-005012-26-CZ A CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES 25/10/2013 
AuthorisedEUCTR2012-005012-26-HR A CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES 05/11/2014 
Not AvailableEUCTR2012-005012-26-SE A CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES 02/10/2014 
AuthorisedEUCTR2012-005012-26-DE A CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES 26/08/2015 
AuthorisedEUCTR2012-005012-26-BG A CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES 19/05/2014 
AuthorisedEUCTR2012-005012-26-LT A CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES 10/06/2014 
RecruitingNCT01964560 Long-term Extension Study to Investigate Lacosamide as an Add-on Therapy in Children With Partial Onset Seizures 14/10/2013 
AuthorisedEUCTR2012-005012-26-PL A CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES 22/01/2014 
02/10/2013 
Not RecruitingYesEUCTR2010-022134-89-HU
Efficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.
Recruitment statusMain IDPublic titleDate of registrationResults available
AuthorisedEUCTR2010-022134-89-SI Efficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries. 15/11/2013 
AuthorisedEUCTR2010-022134-89-ES Efficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries. 01/10/2013 
AuthorisedEUCTR2010-022134-89-IT Efficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries. 20/09/2013 
Not RecruitingEUCTR2010-022134-89-NL Efficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries. 04/10/2013 
Not RecruitingEUCTR2010-022134-89-EE Efficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries. 14/10/2013 
Not RecruitingEUCTR2010-022134-89-LT Efficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries. 24/10/2013 
Not RecruitingEUCTR2010-022134-89-DK Efficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries. 23/01/2014 
AuthorisedEUCTR2010-022134-89-HR Efficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries. 29/08/2014 
AuthorisedEUCTR2010-022134-89-GR Efficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries. 17/01/2014 
AuthorisedEUCTR2010-022134-89-AT Efficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries. 03/02/2014 
Not RecruitingEUCTR2010-022134-89-LV Efficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries. 26/09/2013 
AuthorisedEUCTR2010-022134-89-SK Efficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries. 14/10/2013 
AuthorisedEUCTR2010-022134-89-PT Efficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries. 17/09/2014 
AuthorisedEUCTR2010-022134-89-CZ Efficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries. 17/10/2013 
11/09/2013 
AuthorisedYesEUCTR2013-000951-42-GB
Roxadustat in the treatment of anemia in chronic kidney disease patients
Recruitment statusMain IDPublic titleDate of registrationResults available
AuthorisedEUCTR2013-000951-42-ES FG-4592 in the treatment of anemia in chronic kidney disease patients 31/10/2013 
AuthorisedEUCTR2013-000951-42-SI FG-4592 in the treatment of anemia in chronic kidney disease patients 12/11/2013 
AuthorisedEUCTR2013-000951-42-FR FG-4592 in the treatment of anemia in chronic kidney disease patients 14/05/2014 
AuthorisedEUCTR2013-000951-42-HR FG-4592 in the treatment of anemia in chronic kidney disease patients 03/09/2014 
AuthorisedEUCTR2013-000951-42-LV Roxadustat in the treatment of anemia in chronic kidney disease patients 19/02/2014 
AuthorisedEUCTR2013-000951-42-SE Roxadustat in the treatment of anemia in chronic kidney disease patients 07/03/2014 
AuthorisedEUCTR2013-000951-42-NL Roxadustat in the treatment of anemia in chronic kidney disease patients 04/11/2013 
AuthorisedEUCTR2013-000951-42-IE Roxadustat in the treatment of anemia in chronic kidney disease patients 02/12/2013 
AuthorisedEUCTR2013-000951-42-AT Roxadustat in the treatment of anemia in chronic kidney disease patients 27/11/2013 
AuthorisedEUCTR2013-000951-42-SK Roxadustat in the treatment of anemia in chronic kidney disease patients 11/11/2013 
AuthorisedEUCTR2013-000951-42-HU Roxadustat in the treatment of anemia in chronic kidney disease patients 14/06/2016 
AuthorisedEUCTR2013-000951-42-CZ Roxadustat in the treatment of anemia in chronic kidney disease patients 07/11/2013 
AuthorisedEUCTR2013-000951-42-DE Roxadustat in the treatment of anemia in chronic kidney disease patients 04/09/2013 
AuthorisedEUCTR2013-000951-42-PT FG-4592 in the treatment of anemia in chronic kidney disease patients 25/11/2013 
AuthorisedEUCTR2013-000951-42-FI Roxadustat in the treatment of anemia in chronic kidney disease patients 27/12/2013 
AuthorisedEUCTR2013-000951-42-DK Roxadustat in the treatment of anemia in chronic kidney disease patients 23/12/2013 
AuthorisedEUCTR2013-000951-42-BG Roxadustat in the treatment of anemia in chronic kidney disease patients 09/01/2017 
RecruitingDRKS00008827 A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of FG-4592 in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis 12/08/2015 
Not recruitingNCT02021318 Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa 20/12/2013 
03/09/2013 
      
1 2 3 4 5
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history